Hi! Do you think you might have a spare half hour between now and 4 Jan? We would really value your support. You may have read that NICE, the National Institute for Health and Clinical Excellence has so far refused to approve the use of tocilizumab for GCA. We feel that there are flaws in their arguments, and have sent our comments to them via the consultation website. If you have or have had GCA and have either -
experience of tocilizumab, perhaps through private practice, or -
suffered significantly from steroid side effects or not being able to reduce your dose -
it would be great if you could send your own comments to NICE via the website. We only have till 4 January to do this. You will need to register, and to read the documents, which to be honest are pretty heavy reading. Here's a link to the website: bit.ly/nice_tcz_gca.
And to help you, here's a link to the text of PMRGCAuk's submission: bit.ly/submissionNICE
It would have impact if you could focus your comments around one of the following points -
a) NICE seem to be assuming that 'most people' with GCA are in their 80s
b) they have approved it for Takiyasu's Arteritis, which is very similar to GCA. In doing so they referred as evidence to a trial with GCA patients!
c) the 'burden' of long term steroid doses in terms of side effects and long term complications is life-changing for patients
d) TCZ targets the cause of the symptoms rather than just the symptoms. It is the first specific new treatment for GCA in over 60 years, i.e. in the lifetime of many people who are now suffering from GCA.
Thanks, and have a joyful Christmas and a healthy New Year!